Illumina Announces High Density Expansion to iSelect(R) Custom Genotyping Platform

Illumina, Inc. (NASDAQ:ILMN) today launched the Infinium(R) HD (High Density) iSelect Custom Genotyping solution. Researchers now have the flexibility to screen SNPs ranging from 3,000 to 200,000 in focused genotyping studies for both human and non-human species. This higher-density iSelect Custom Genotyping technology is the most versatile solution of its kind in the industry. It offers high data quality, high-throughput capabilities, and flexible sample multiplexing to screen any SNP in any species.

Source: Illumina